Multi-component-multistage malaria vaccines

US10183066B2 · kind B2 · utility

Assignee

• Fraunhofer-Gesellschaft zur förderung der angewandten Forschung e.V. · DE

Inventors

• Alexander Boes · Cologne, DE
• Holger Spiegel · Aachen, DE
• Gueven Edgue · Aachen, DE
• Veronique Beiss · Aachen, DE
• Markus Sack · Aachen, DE
• Andreas Reimann · Krefeld, DE
• Rainer Fischer · Monschau, DE

Key dates

• Filing date: Mar 27, 2015
• Grant date: Jan 22, 2019
• Expiry date: Mar 27, 2035

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such proteins; Antibodies induced or generated by the use of said malaria vaccines or said nucleic acid molecules encoding said proteins and/or fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy.